Chronic graft-versus-host-disease (cGVHD) is a multisystem alloimmune and autoimmune complication and a major cause of late non-relapse morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HCT) [1]. Among patients with cGVHD, up to 20% develop sclerotic disease in their initial 3 years following systemic treatment of cGVHD (sGVHD) [2]. Treatment of sclerotic disease remains a challenging need due to its refractory nature.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Resat
Contact Resat, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack